BMS Response to the European Commission Call for Evidence: Biotech Act II Bristol Myers Squibb (BMS) welcomes the European Commission's Call for Evidence for the Biotech Act II and commends the initiative's ambition to build a more competitive, innovation-friendly regulatory environment for industrial biotechnology and biomanufacturing in the EU.
BMS
Bristol Myers Squibb
Company · Belgium · EU Transparency Register 04437556781-76
1
position filed
in the 326 files tracked
1
legislative file
of 326 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #602 by legislative files engaged — a count of participation, not a measure of influence.
4
declared lobbying FTE
self-declared
€2.5M+
declared costs / yr (floor)
5
EP accreditations
as declared to the register
2011
in the register since
Declares membership of
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- EFPIA Oncology Platform
- EFPIA Cardiovascular Health Platform
- EFPIA Alzheimer's Platform
- DigitalEurope →
- European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) →
- Friends of Europe
- American Chamber of Commerce to the EU →
- American European Community Association (AECA)
- European Patients' Forum
- EURORDIS
- TRANSFORM Alliance
- and 1 more
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Registered as
- Bristol-Myers Squibb Company (BMS)
- Head office
- Princeton, New Jersey, United states
- EU office
- Ixelles
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Bristol in PolicySpeak: request access →
Work at Bristol Myers Squibb? so we know who speaks for it.
Their record over time
Bristol Myers Squibb filed 1 position on 9 Jun 2026, across 1 of the 326 legislative files tracked here.
What they argued
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Is this your organization?
Everything on this page comes from Bristol Myers Squibb’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.